This National Cancer Survivors Month, your gift is matched to expand treatment options and bring more patients into survivorship through Project Cure CRC.
The Colorectal Cancer Alliance’s philanthropic research fund, Project Cure CRC, has announced another awardee. Kevin Van Der Jeught, Ph.D., of the University of Miami, will receive $200,000 over two years.
The Colorectal Cancer Alliance’s philanthropic research fund, Project Cure CRC, has announced another awardee. Peter P. Lee, MD, of City of Hope will receive $1 million over two years.
A veteran in the field of gastrointestinal cancer research, Dr. Marshall will share his leadership experience and scientific expertise to guide the Alliance’s patient support and research initiatives, particularly Project Cure CRC.
The Colorectal Cancer Alliance is committed in 2024 to finally getting Congress to include colorectal cancer as a dedicated research program at the CDMRP.
Our nation’s investment in cancer research and prevention is saving lives. Cancer mortality rates have declined by 33% since 1990, and the Biden administration’s Cancer Moonshot has a goal of 50%.
Developing a Lynch Syndrome vaccine could change the narrative for patients, reducing screenings and – more importantly – lowering risks for Lynch Syndrome-related cancers.
Lynch Syndrome is the most common cause of hereditary colorectal cancer, resulting in 4,200 cases per year. It is also more common in younger adults than in other forms of colorectal cancer.
Driven by a commitment to save lives through best practices and innovation in research participation, the group offered collaborative solutions to improve trial design, messaging, access, and navigation, and ultimately, increase participation.
Results of a new study announced at the 2023 ASCO Gastrointestinal Cancers Symposium demonstrate that a combination therapy, trifluridine/tipiracil (Lonsurf) plus bevacizumab, has promising activity to increase lifespan in mCRC patients.
hrough Project Cure CRC, the Alliance is fueling bold, early-stage research with the potential to transform colorectal cancer treatment. Dr. Lisa Mielke’s groundbreaking work explores how the gut’s immune system and nerve signaling influence cancer growth—opening the door to new therapeutic approaches, including repurposed existing drugs. This is what’s possible when promising ideas get the support they need to move forward.